4. (Amended) A compound of formula **(I)** according to claim 1 wherein R^2 is attached to a ring carbon and is selected from fluoro, chloro, bromo, cyano, methyl, methoxy, ethylthio, 2-hydroxyethylthio or 2-dimethylaminoethylthio and m is 0-2; wherein the values of R^2 may be the same or different;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

5. (Amended) A compound of formula **(I)** according to claim 1 wherein R^3 is fluoro, chloro, bromo or sulphamoyl; and p is 1;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

6. (Amended) A compound of formula **(I)** according to claim 1 wherein R^4 is methyl, ethyl, methoxy, methylthio, acetyl, benzyloxy, mesyl, *N,N*-diethylaminoethoxy, 3-*N,N*-dimethylamino-2-hydroxypropoxy, phenoxy, *N*-methylcarbamoyl, *N,N*-dimethylcarbamoyl, *N*-(3-imidazol-1-ylpropyl)carbamoyl, *N*-[3-(2-oxo-pyrrolidin-1-yl)propyl]carbamoyl, 3,5-dioxapiperidin-1-ylsulphonyl, *N*-cyclopropylsulphamoyl, *N*-cyclopropylmethylsulphamoyl, anilinosulphonyl, *N*-pyrimidin-2-ylsulphamoyl, *N*-methylsulphamoyl, *N*-propylsulphamoyl, *N*-(2-methoxyethyl)sulphamoyl, *N*-(2-methylaminoethyl)sulphamoyl, *N*-(2-isopropylaminoethyl)sulphamoyl, *N*-(2-dimethylaminoethyl)sulphamoyl, *N*-(2-diethylaminoethyl)sulphamoyl, *N*-[2-(hydroxyethylamino)ethyl]sulphamoyl, *N*-[2-(diethylaminoethyl)ethyl]sulphamoyl, *N*-(pyrrolidin-1-ylethyl)sulphamoyl, *N*-[2-(1-methylpyrrolidin-2-yl)ethyl]sulphamoyl, *N*-(2-piperidin-1-ylethyl)sulphamoyl, *N*-(2-piperazin-1-ylethyl)sulphamoyl, *N*-(2-morpholinoethyl)sulphamoyl, *N*-(2-imidazol-4-ylethyl)sulphamoyl, *N*-(3-hydroxypropyl)sulphamoyl, *N*-(2,3-dihydroxypropyl)sulphamoyl, *N*-(3-methoxypropyl)sulphamoyl, *N*-(3-aminopropyl)sulphamoyl, *N*-(3-methylaminopropyl)sulphamoyl, *N*-(3-dimethylaminopropyl)sulphamoyl, *N*-(3-diethylaminopropyl)sulphamoyl, *N*-(3-isopropylaminopropyl)sulphamoyl, *N*-(3-*t*-butoxycarbonylaminopropyl)sulphamoyl, *N*-(3-benzyloxycarbonylaminopropyl)sulphamoyl, *N*-[3-(2-oxopyrrolidin-1-yl)propyl]sulphamoyl, *N*-(3-morpholinopropyl)sulphamoyl,

N-[3-(4-methylpiperazin-1-yl)propyl]sulphamoyl, *N*-(3-imidazol-1-ylpropyl)sulphamoyl or *N*-(5-hydroxypentyl)sulphamoyl; and q is 1;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

7. (Amended) A compound of formula **(I)** according to claim 1 wherein Ring B is phenyl;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Please add the following new claims 13 -17:

13. A method for producing an anti-cancer effect in a warm blooded animal in need thereof which comprises administering to said animal an effective amount of a compound of the formula (I) as claimed in any one of claims 1 – 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

14. A method for producing an anti-proliferative effect in a warm blooded animal in need thereof which comprises administering to said animal an effective amount of a compound of the formula (I) as claimed in any one of claims 1 – 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

15. A method for producing a CDK2 inhibitory effect in a warm blooded animal in need thereof which comprises administering to said animal an effective amount of a compound of the formula (I) as claimed in any one of claims 1 – 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

16. A method for treating a disease or medical condition mediated in whole or in part by CDK2, which method comprises administering to a warm blooded animal in need thereof a CDK2 inhibitory effective amount of a compound of the formula (I) as claimed in any one of claims 1 – 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

A2

17. The method of claim 16 wherein said disease or medical condition is a cancer selected from solid tumours and leukemias.